Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2201]

Lower dose, less toxic radiopharmaceutical produces better outcomes

Lower dose, less toxic radiopharmaceutical produces better outcomes

More collaboration between primary care and oncology may improve fragmented cancer care

More collaboration between primary care and oncology may improve fragmented cancer care

Globalisation of cancer clinical trials linked to lower enrolment of Black patients

Globalisation of cancer clinical trials linked to lower enrolment of Black patients

FDA approves lorlatinib for metastatic ALK-positive NSCLC

FDA approves lorlatinib for metastatic ALK-positive NSCLC

Tissue, scaffold technologies provide new options for breast cancer, other diseases

Tissue, scaffold technologies provide new options for breast cancer, other diseases

$FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma$

FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression

Tucatinib authorised by UK’s MHRA for locally advanced or metastatic HER2-positive breast cancer

Tucatinib authorised by UK’s MHRA for locally advanced or metastatic HER2-positive breast cancer

Medication-based starvation of cancer cells

Medication-based starvation of cancer cells

New data from the phase 3 CLEAR trial demonstrate significant improvement in progression free survival and overall survival versus standard of care in advanced renal cell carcinoma

New data from the phase 3 CLEAR trial demonstrate significant improvement in progression free survival and overall...

More from ecancer